%D8%B1%D9%8A%D9%84%D8%A8%D9%8A%D9%81%D9%8A%D8%B1%D9%8A%D9%86Category:RilpivirineRilpivirinRilpivirineRilpivirinaRilpivirineRilpivirinRilpivirina%D0%A0%D0%B8%D0%BB%D0%BF%D0%B8%D0%B2%D0%B8%D1%80%D0%B8%D0%BDRilpivirinRilpivirinRilpivirin%D0%A0%D1%96%D0%BB%D0%BF%D1%96%D0%B2%D1%96%D1%80%D0%B8%D0%BDRilpivirineQ421547
about
P3781
A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsSafety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeEfficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected PatientsA Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral MedicinesDolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.The Rilpivirine Cerebrospinal-fluid (CSF) StudyA Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of DigoxinTMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- PositNeurocognitive Function Improvement After Switching From Efavirenz to RilpivirineA Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) InfectionMore Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsEffect on HIV Medications on EPC CellsDarunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantDarunavir and Rilpivirine Interactions With Levonorgestrel ImplantStudy to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, AntTMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirStudy to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STRA Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersStudy to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DFTMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy ParticipantsA Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult SubjectsA Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative ParticipantsDose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineThe LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifEA Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentA Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsSwitching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological SuppressionDolutegravir + Rilpivirine Switch Study (DORISS)Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side EffectsRegimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve SubjectsRegimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
P4844
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug designDevelopment of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulationAntiviral drug allergy.Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.Biochemical mechanism of HIV-1 resistance to rilpivirine.Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.Rilpivirine: a new addition to the anti-HIV-1 armamentarium.Rilpivirine.Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineRilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.Researcher presents vexing information on rilpivirine.Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.Rilpivirine and complera: new first-line treatment optionsPrevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance DatabaseEfficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled TrialEfficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practiceEffectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitorsGenotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysisBoceprevir, telaprevir, and rilpivirine hydrochloride
P921
Q61956164-CDC36533-019A-4015-9D3E-8A028959C0ACQ61974992-6927A9CC-2AD1-4D56-A386-628E4E9A895EQ62062070-940C9479-4CFD-400E-B9AF-89A1CDF6610DQ62105271-1F94303D-272D-414D-A5E6-A1BF4B8E003DQ62817257-097BE7DA-C30B-445A-83D2-A50AD6D7326AQ63062312-3912893F-2843-4CCC-9C6E-19928256D6B0Q63062315-FD0AD55A-D3B4-4AB2-8D1F-4CF5A6772B02Q63062663-2E5FF077-A84C-42E6-93C3-0D3C2B10CBF1Q63062918-915BA727-5BBB-4061-AA3C-945BCBF82ADBQ63063267-2AA99A82-F490-4B75-995B-D82CF571F4A8Q63316094-A2F5BB4A-DC57-46F4-8169-5835979836BAQ63320817-3B0CCCD0-2580-4ECF-9113-1894F4049AC1Q63335785-D8AB7630-6E89-420A-8D95-4A92038089FEQ63393835-9917D39E-17D9-4204-ACF6-1F201EB57D64Q63397954-DCB4D587-64AE-4132-B063-C83CC81ED5E2Q63399137-1D78C8FE-59F2-4EDB-9A80-F78275CAD6A4Q63574348-8B3F66F7-C985-4B0B-A9E8-DAE97EECF3E6Q63593687-96A37048-BFDB-4053-AF38-76B4326F5D6BQ63600044-B0434201-9A61-476E-93A3-FFC1F258D38CQ63600046-1B7F6C04-8199-4D28-8294-A6D276CC00C9Q63813621-5CD15EC7-EBD9-457B-BB61-7B756121351FQ63814300-FA4E8A27-1D1F-4C4C-98A6-08A3CE339B03Q63814453-A7B7A436-1B58-41CB-B4BD-DAF720D3BE7FQ63816237-886342AA-17DE-4F79-8808-8B8D685424E5Q63818648-815F34FD-C0F2-41CA-882A-3B7F2760C4B7Q63837046-4B50A828-E960-4CC3-8767-0EFE16F71045Q63842924-31BD82B8-4646-445B-9713-F1E8BDDCFD20Q63843457-03BDC5BB-423F-4EEE-973C-09801DFE895FQ64029834-99FFABC3-9C50-482B-85B1-804163B1F3D0Q64030482-4F2DE45A-08C9-4757-996E-3E26F9DF2A93Q64149754-5A2AED88-BAB0-4C7A-AB4D-866ED57D953DQ64150518-E13DD4C6-2F9A-4D87-8BD8-614735F79550Q64171377-C0460775-0D32-4D8C-A6F9-F76B63C25BFCQ64172020-79A00973-AAA0-4294-8A04-DB5E888C3059Q64189636-7D0CCAF2-80B9-4683-AF66-61D046DC18FBQ64222761-2910C772-90C6-4153-8DEC-4CFC85B113F3Q64348855-91A30240-5DF7-4EFC-B0CA-4D9FCFF96528Q64363802-B60F03AD-4846-452D-9918-F9440D3239A5Q64393489-6B4E985B-12B8-4A48-837F-6AA34569FCDDQ64394252-0E8CF7F1-2172-4EC0-B0AE-89629A5EECB6
P4844
Q27661231-243DDE5F-D211-4168-B53F-E0128F401E7AQ33423563-4798EFC7-8DD0-47F4-BC37-84572C33D029Q33826308-F7F1354C-592A-4FD5-A41C-76D311DF2097Q34075812-C3105AFF-0C7A-4B04-BA77-40EEE2FA9131Q34316101-A01F2DA3-51E0-4328-B0ED-BDD9227583A1Q35557326-C0972971-DBB7-45F4-9DF2-F65E220CE3B8Q35939695-21C8FFFA-1025-4694-A0BB-07839B2C74F0Q36018903-EB939A7B-10DA-4ABC-BC74-15F18E917727Q36368294-3D13B1D1-8D24-4CFD-9BC6-7D83B5399224Q37403454-0F64AA8D-B8D0-4982-92C6-5D79279841CEQ37528451-9E2D81C7-B7C9-4278-B6E9-628B1CDA5171Q37579219-5D69180B-2C80-44DD-80E2-BF17AE8F318FQ37849594-BD9C02D2-78C1-4421-B53B-16F8C38CF446Q37987209-85B444A1-DAC6-412F-B704-23E4DAC950B3Q38002686-FB9DB705-EC3E-44AA-A791-EC3BCE374146Q38033413-3ADDE4D7-A135-4E26-B7F7-8BED70B6F441Q39382195-CEBA5C5A-CA6A-4F0C-AFB5-5B406B76E1D6Q40445987-E76DA6A6-0052-49B2-B512-1344D35EA19EQ41807080-EAF3F4A8-6719-4D50-81A9-2CFDAAF57D08Q42718706-74C8383E-6690-4628-AE1C-6AD49D269F9CQ43683920-42992115-66DC-49CA-B5AA-F1DAC2533262Q44513458-A1453C27-674E-4C7A-9AF1-4EDF6F047CB1Q44795186-EB8AE92D-9F41-4EFF-8CEA-6EE98A43180AQ45106142-22A59D8B-04D5-45CD-8A45-A0A086C145A5Q45414505-33D75A17-5502-4910-BE01-FDC43E62D237Q46219694-043DD652-6702-444F-865F-08AFD5AD70CDQ46772762-F1BB10EA-97A4-4225-AFF0-BF65C3A020B3Q48246306-3CE604CE-3981-48A0-91BE-AE317F189E27Q51520320-4E1F3541-97D0-4E75-AF90-1AFDC91F4431Q51533517-E9C57204-F854-4F07-A31C-B8BD6C48BF9DQ51547763-DEDE420B-303B-4691-9859-DC7364BEF60CQ54532972-0464DE94-FC83-44DC-A0FF-321248D6F350Q56896676-8A486760-3014-46E4-B36D-7B9406098BEFQ61218072-C0813BC6-9492-4982-81F5-2869690E1A37Q64056259-DAC4CF96-E699-4322-BC66-66CE6F568DA9Q64070179-D2EE3B74-A155-4155-A4FA-31F3D69CC439Q64086178-462D2338-156D-4FFA-BB5B-E43663011498Q64245499-5616ED2E-45D0-4B31-BF77-4DB7FCF007AEQ82428879-35EA34CD-AE6A-41CE-AC29-06894D47463FQ83275583-C5132A4A-43F5-406F-8D47-A3A8029DBB03
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Rilpivirin
@de
Rilpivirin
@hu
Rilpivirin
@sh
Rilpivirin
@sl
Rilpivirin
@sr
Rilpivirina
@es
Rilpivirine
@nl
Rilpivirine
@vi
rilpivirina
@pt
rilpivirine
@en
type
label
Rilpivirin
@de
Rilpivirin
@hu
Rilpivirin
@sh
Rilpivirin
@sl
Rilpivirin
@sr
Rilpivirina
@es
Rilpivirine
@nl
Rilpivirine
@vi
rilpivirina
@pt
rilpivirine
@en
altLabel
4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
@en
500287-72-9
@fr
C22H18N6
@fr
Edurant
@es
Edurant
@pt
R-278474
@en
Rilpivirine
@pt
TMC 278
@en
TMC-278
@en
TMC278
@en
prefLabel
Rilpivirin
@de
Rilpivirin
@hu
Rilpivirin
@sh
Rilpivirin
@sl
Rilpivirin
@sr
Rilpivirina
@es
Rilpivirine
@nl
Rilpivirine
@vi
rilpivirina
@pt
rilpivirine
@en